resmetirom Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Thyroid hormone receptor-beta partial agonist; small-molecule pharmaceutical compound compound Reference approved

Also known as: MGL-3196, VIA-3196, Rezdiffra

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

60 mg, 80 mg, 100 mg

Storage

For the labeled tablet product: store at 20°C to 25°C (68°F to 77°F), with permitted excursions from 15°C to 30°C (59°F to 86°F).

Solubility

Low aqueous solubility below pH 6; higher solubility above pH 7, reported as 0.44 mg/mL at pH 7.04.

Catalog Description

Resmetirom is a synthetic small molecule that selectively activates thyroid hormone receptor-beta, the predominant thyroid hormone receptor isoform in the liver. Its molecular formula is C17H12Cl2N6O4 and its molecular weight is 435.22 g/mol. The compound is indicated in the United States, under the name Rezdiffra, for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis, in conjunction with diet and exercise.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Median terminal plasma half-life: 4.5 hours.

Onset

A clinical onset time is not established in the cited sources. Median time to maximum plasma concentration is approximately 4 hours after repeated daily administration; steady state is typically reached within 3 to 6 days.

Administration Routes (Research)

oral

Reported Research Effects

Activates thyroid hormone receptor-beta as a partial agonist.
Reduces liver fat content and liver stiffness markers in clinical pharmacodynamic assessments; the clinical relevance of these marker changes remains to be confirmed.
Decreases circulating prohormone free T4, with minimal changes in active T3 or TSH reported in the prescribing information.
Increases sex hormone-binding globulin concentrations; the clinical significance of this change is unknown.
Commonly reported adverse reactions include diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness.
Important labeled safety findings include hepatotoxicity and gallbladder-related adverse reactions.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

The current DailyMed label was updated in July 2026. U.S. approval was granted on March 14, 2024, under the accelerated-approval pathway for noncirrhotic MASH with moderate to advanced fibrosis. The cited sources describe tablet strengths of 60 mg, 80 mg, and 100 mg and oral administration; they do not establish a general research-material presentation or noncommercial reference size.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 920509-32-6; PubChem CID 15981237; UNII RE0V0T1ES0; ChEMBL CHEMBL3261331; molecular formula C17H12Cl2N6O4; molecular weight 435.22 g/mol; InChIKey FDBYIYFVSAHJLY-UHFFFAOYSA-N; IUPAC name 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile

Source-Backed Observations

Resmetirom is a partial agonist of thyroid hormone receptor-beta. In an in vitro functional assay, it produced 83.8% of the maximum response of triiodothyronine at THR-beta, with an EC50 of 0.21 micromolar. THR-beta activation in the liver is associated with reduced intrahepatic triglycerides. Resmetirom is metabolized by CYP2C8; its major metabolite is MGL-3623. It is greater than 99% protein-bound and is also an inhibitor of CYP2C8, OATP1B1, OATP1B3, and BCRP according to the current U.S. prescribing information.

Reflects published research. Educational reference — not a recommendation for use.

Sources

Resmetirom Compound Summary
https://pubchem.ncbi.nlm.nih.gov/compound/Resmetirom (accessed 2026-09-01)

REZDIFFRA (resmetirom) Prescribing Information and Drug Label
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e67ea09f-a840-439c-86c8-f98585f978b2 (accessed 2026-09-01)

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (accessed 2026-09-01)

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
https://pubmed.ncbi.nlm.nih.gov/38324483/ (accessed 2026-09-01)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.